Delving into the Latest Updates on Treprostinil sodium with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

Dry powder formulation of treprostinil(MannKind Corporation), TETON, TREPROSTINIL

+ [23]

Target

PGI2 receptor

Action

agonists

Mechanism

PGI2 receptor agonists(Prostanoid IP receptor agonists)

Therapeutic Areas

Respiratory DiseasesOther DiseasesImmune System Diseases+ [3]

Active Indication

Hypertension, PulmonaryLung Diseases, InterstitialChronic thromboembolic pulmonary hypertension+ [12]

Inactive Indication

Anemia, Sickle CellCalcinosisChronic Limb-Threatening Ischemia+ [13]

Originator Organization

United Therapeutics Corp.

Active Organization

United Therapeutics Corp.Ferrer Internacional SA

Aop Orphan Pharmaceuticals GmbH

+ [10]

Inactive Organization

Lee's Pharmaceutical Holdings Ltd.

MannKind Corp.

License Organization

Liquidia Corp.

Mochida Pharmaceutical Co., Ltd.

Pharmosa Biopharm, Inc.

+ [5]

Drug Highest PhaseApproved

First Approval Date

United States (21 May 2002),

Pulmonary Arterial Hypertension

RegulationAccelerated Approval (United States), Orphan Drug (United States), Priority Review (China), Orphan Drug (South Korea), Orphan Drug (Japan)

Login to view timeline

Structure/Sequence

Molecular FormulaC23H34NaO5

InChIKeyRCKWZOAISRYANP-ZSESPEEFSA-N

CAS Registry289480-64-4

Pulmonary Arterial Hypertension (PAH) is a serious condition that puts strain on the right side of the heart. While oral medications can help, many patients with intermediate-risk PAH may not see enough improvement, and their heart function can continue to decline.
This study aims to find out if adding an injectable medication, Treprostinil, to a patient's current oral PAH therapy can improve heart function and overall health. This is a single-arm study, which means all participants will receive the study treatment.
The main goal is to measure the change in the amount of blood the right side of the heart pumps with each beat (Right Ventricular Stroke Volume, or RVSV) after 3 months of treatment. This will be measured using a specialized heart scan called Cardiac Magnetic Resonance Imaging (CMR). Researchers will also assess changes in exercise ability (with a 6-minute walk test), blood markers, and patient symptoms.
Participants will be in the main part of the study for 3 months, with follow-up for a total of 24 months to monitor the long-term effects and safety of the treatment.

Start Date31 Oct 2025

Sponsor / Collaborator-

NCT06603285

/ Not yet recruitingNot Applicable

A Multi-center, Prospective Study to Observe the Safety, Tolerability, and Efficacy of Remodulin® in Patients With Pulmonary Arterial Hypertension

This is a multi-center, single-arm, prospective study to enroll patients diagnosed as pulmonary arterial hypertension. The objective in this study is to observe the efficacy and safety of treprostinil in subjects with pulmonary arterial hypertension.

Start Date16 Oct 2025

Sponsor / Collaborator

Excelsior

NCT07116681

/ Not yet recruitingEarly Phase 1IIT

The Acute Effects of Dry Powder Inhaled Treprostinil on Stroke Volume Augmentation and Dead Space Ventilation in Patients With Exercise-induced Pulmonary Hypertension

This study aims to investigate therapies for exercise induced pulmonary hypertension (EiPH). This is a condition that effects the blood vessels in the lungs and causes shortness of breath with activity. Currently, there are very limited treatment options for this condition. Inhaled treprostinil, also known as Tyvaso, is a medication used to treat other forms of lung disease and is safe and well tolerated. This study will measure the ability of Tyvaso to improve symptoms related to EiPH and improve performance on exercise testing.

Start Date01 Oct 2025

Sponsor / Collaborator

University of California San Diego

[+1]

100 Clinical Results associated with Treprostinil sodium

Login to view more data

100 Translational Medicine associated with Treprostinil sodium

Login to view more data

100 Patents (Medical) associated with Treprostinil sodium

Login to view more data

833

Literatures (Medical) associated with Treprostinil sodium

01 Nov 2025·RESPIRATORY MEDICINE

BREEZE Optional Extension Phase: Long-term safety and efficacy of treprostinil dry powder inhaler (Tyvaso DPI) in pulmonary arterial hypertension

Article

Author: Desai, Sapna ; Mehta, Jinesh P ; Shah, Trushil G ; Thrasher, Claire M ; Bajwa, Abubakr A ; Sahay, Sandeep ; Fisher, Micah R ; Eggert, Michael S ; Restrepo-Jaramillo, Ricardo ; Ramani, Gautam V ; Broderick, Meredith ; Palevsky, Harold ; Spikes, Leslie A ; Smith, Peter ; El-Kersh, Karim ; Johri, Shilpa ; Joly, Joanna M ; Deng, Chunqin ; Shapiro, Shelley M ; Burger, Charles D

INTRODUCTION:

Pulmonary arterial hypertension (PAH) is a rare and progressive disease associated with significant morbidity and mortality. Prostacyclins, including treprostinil, are a mainstay of PAH treatment, particularly in patients with intermediate to high risk of death. Following the approval of treprostinil inhalation solution for PAH, treprostinil dry powder inhaler (DPI) was developed as a small, portable, low-maintenance device to improve patient experience.

OBJECTIVE:

The primary objective of the BREEZE study was to assess the safety and tolerability of treprostinil DPI in PAH.

METHODS:

BREEZE was a 3-week, single-arm, open-label study in which patients with PAH transitioned from a stable dose of treprostinil inhalation solution to a comparable dose of treprostinil DPI.

RESULTS:

Following the 3-week treatment phase, 49 of 51 patients opted to enroll in the Optional Extension Phase (OEP). Throughout the OEP, 6MWD continued to increase with a median change from baseline of 16 m at week 107 and over a third of patients experiencing an improvement of at least 30 m. Patient satisfaction with the DPI device was overwhelmingly positive while drug-related adverse events were infrequent and characteristic of prostacyclin therapy.

CONCLUSION:

The BREEZE OEP successfully demonstrated the safety of long-term treatment with treprostinil DPI in patients with PAH.

CLINICAL TRIAL REGISTRATION:

NCT03950739.

01 Nov 2025·Respiratory Medicine and Research

Acute hemodynamic response to inhaled treprostinil in pulmonary hypertension associated with interstitial lung disease: a case highlighting unresolved questions

Letter

Author: Riou, Marianne ; Hirschi, Sandrine ; Canuet, Matthieu ; Montani, David ; Turquier, Ségolène

01 Nov 2025·AUTOIMMUNITY REVIEWS

Unmet needs and emerging pharmacotherapies for autoimmune connective tissue disease-associated interstitial lung diseases

Review

Author: Inoue, Yoshikazu ; Kondoh, Yasuhiro ; Fujii, Takao ; Atsumi, Tatsuya

Autoimmune connective tissue disease associated with interstitial lung disease (CTD-ILD) includes rheumatoid arthritis-associated ILD, systemic sclerosis-associated-ILD, and several other ILDs. Many patients with CTD-ILD-as well as individuals with other ILDs-develop a progressive pulmonary fibrosis (PPF) similar to idiopathic pulmonary fibrosis (IPF). PPF is characterized by worsening respiratory symptoms, declining lung function despite current pharmacotherapies, and ultimately early death. Current pharmacotherapies for CTD-ILD and PPF include glucocorticoids, immunosuppressants, and anti-fibrotic agents. Due to the scarcity of randomized clinical trials for CTD-ILD, many pharmacotherapies are generally administered off-label (although several are approved in Japan), with notable exceptions including nintedanib, an anti-fibrotic agent approved for SSc-ILD and chronic progressive fibrosing ILD in several countries. As the available agents only slow the decline of pulmonary function and are associated with treatment-limiting side effects, there is a need for more efficacious and tolerable pharmacotherapies for CTD-ILD and PPF. Promising compounds in clinical trials include nerandomilast (a preferential phosphodiesterase 4B inhibitor), admilparant (a lysophosphatidic acid receptor 1 antagonist), and inhaled treprostinil (a prostacyclin analogue). Nerandomilast may have both anti-fibrotic and immunomodulatory properties; in preclinical models of PPF, it reduced neutrophils and macrophages and down-regulated pro-fibrotic signaling pathways. Hopefully, therefore, this pipeline will produce new medications to ease the collectively large burden of CTD-ILD and PPF.

186

News (Medical) associated with Treprostinil sodium

13 Oct 2025

·ir.unither.com

United Therapeutics to Feature Clinical Data at the CHEST 2025 Annual Meeting

SILVER SPRING, Md., & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)-- United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced two presentations at the upcoming CHEST 2025 Annual Meeting hosted by the American College of Chest Physicians taking place October 19-22, 2025, in Chicago. In addition, United Therapeutics will sponsor and host several events including the PHinding Pulmonary Hypertension: Exploring Best Practices in PH-ILD Detection and Management dinner symposium and the Women in Chest Medicine Annual Luncheon. “CHEST is a powerful platform for United Therapeutics and the pulmonary hypertension community to connect, share new developments, and elevate patient care,” said Andrew Nelsen, PharmD, VP of Global Medical Affairs. “We’re excited to sponsor the ‘PHinding Pulmonary Hypertension’ symposium and showcase rapid-fire presentations, including real-world data on earlier inhaled treprostinil use and its impact on hospitalization rates, plus new insights from the PHINDER study to refine screening for PH-ILD.” Oral Presentations include: Rapid fire original investigation presentation, Tuesday, October 21, 10:44 a.m. to 10:48 a.m. CDT: Rapid Area 4D/4075 – Echocardiographic Features of Patients with Pulmonary Hypertension Associated with Interstitial Lung: Interim Analysis of the PHINDER Study. Presented by Tejaswini Kulkarni, M.D., MPH, FCCP, University of Alabama at Birmingham. Rapid fire original investigation presentation, Tuesday, October 21, 2:03 p.m. to 2:07 p.m. CDT: Rapid Area 3D/4073 – Impact of Inhaled Treprostinil Initiation Timing on Hospitalizations in Patients with PH-ILD.Presented by Karim El-Kersh, M.D., University of Arizona. Sponsored and hosted events include: The 2025 Pulmonary and Critical Care Medicine Fellows Breakfast, Saturday, October 18, 6:15 a.m to 7:15 a.m. CDT. This session will be a case-based session addressing the complex disease state of interstitial lung disease and pulmonary hypertension. The Women in Chest Medicine Annual Luncheon,Monday, October 20, 12:00 p.m. to 1:30 p.m. CDT. Cheers and Challenges: Game On! (for APPs), Monday, October 20, 5:30 p.m. to 7:00 p.m. CDT. Join fellow advanced practice providers for an evening of friendly competition and connection. PHinding Pulmonary Hypertension: Exploring Best Practices in PH-ILD Detection and Management, Monday, October 20, 6:00 p.m. to 9:00 p.m. CDT. United Therapeutics: Enabling Inspiration At United Therapeutics, our vision and mission are one. We use our enthusiasm, creativity, and persistence to innovate for the unmet medical needs of our patients and to benefit our other stakeholders. We are bold and unconventional. We have fun, we do good. We are the first publicly-traded biotech or pharmaceutical company to take the form of a public benefit corporation (PBC). Our public benefit purpose is to provide a brighter future for patients through (a) the development of novel pharmaceutical therapies; and (b) technologies that expand the availability of transplantable organs. You can learn more about what it means to be a PBC here: unither.com/pbc. Forward-Looking Statements Statements included in this press release that are not historical in nature are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, among others, statements regarding anticipated presentations and other events at the upcoming CHEST Annual Meeting, our efforts to innovate for the unmet medical needs of our patients, to benefit our other stakeholders, and to pursue our public benefit purpose of developing novel pharmaceutical therapies and technologies that expand the availability of transplantable organs. These forward-looking statements are subject to certain risks and uncertainties, such as those described in our periodic reports filed with the Securities and Exchange Commission, that could cause actual results to differ materially from anticipated results. Consequently, such forward-looking statements are qualified by the cautionary statements, cautionary language, and risk factors set forth in our periodic reports and documents filed with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K. We claim the protection of the safe harbor contained in the Private Securities Litigation Reform Act of 1995 for forward-looking statements. We are providing this information as of October 13, 2025, and assume no obligation to update or revise the information contained in this press release whether as a result of new information, future events or any other reason. View source version on businesswire.com: https://www.businesswire.com/news/home/20251013658816/en/ For Further Information Contact: Investors https://ir.unither.com/contact-ir Media mrteam@unither.com Source: United Therapeutics Corporation

09 Oct 2025

·www.pharmaceutical-technology.com

Boehringer’s Jascayd nets first FDA IPF approval in over 10 years

German pharma Boehringer Ingelheim has obtained FDA approval for its disease-modifying therapy, Jascayd (nerandomalist) in IPF, making it the first treatment to be approved in this indication in more than a decade. Image credit: Fagreia via ShutterStock.com. Boehringer Ingelheim’s Jascayd (nerandomalist) has got the US Food and Drug Administration (FDA) nod in idiopathic pulmonary fibrosis (IPF), making it the first drug to be approved in this indication in more than a decade. The preferential phosphodiesterase 4B (PDE4B) inhibitor is a first in its class that acts by exerting immunomodulatory and antifibrotic effects. These contribute to the slowing of lung function decline in patients. The drug obtained the FDA go-ahead after two positive Phase III readouts, including the FIBRONEER-ILD (NCT05321082) and FIBRONEER-IPF (NCT05321069) studies. During these trials, Jascayd was found to boost lung function by slowing forced vital capacity (FVC) decline. Following its market debut, Scott Staszak, president and CEO of the Pulmonary Fibrosis Foundation, noted that Jascayd could fulfil the “long-standing need for new treatment options in IPF”. According to Staszak, the drug will also provide an important addition to IPF’s treatment landscape , which has lain dormant since the approval of anti-fibrotics pirfenidone and Boehringer’s Ofev (nintedanib), for which generics are now marketed. Jascayd could set a new standard in IPF Since the respective approvals of pirfenidone and nintedanib in IPF, these two drugs have been the standard of care (SoC) for patients, though they are commonly associated with strong side effects. This includes severe liver damage, meaning patients with compromised liver function may not be able to take this combination. GlobalData Strategic Intelligence US Tariffs are shifting - will you react or anticipate? Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis. By GlobalData Learn more about Strategic Intelligence According to analysts in GlobalData’s Immunology team, Jascayd approval will be a positive development for patients. “Jascayd is a new, effective treatment with a similar side effect profile to placebo,” which they note will be a welcome advance for those unable to tolerate currently approved therapies. Over time, analysts forecast that the drug will obtain patient share from pirfenidone-nintedanib, allowing the drug to “further penetrate the IPF market”. They also predict the drug’s clinical uptake to be swift, citing its “strong clinical backing and favourable safety profile,” as well as the “flexibility to use Jascayd alone or alongside existing treatment.” IPF market set for future growth Though the IPF market had not seen new blood since 2014, the indication’s dynamic appears to be shifting , as a big pharma and biotech push has seen a range of hopefuls reach late-stage trials. This includes Bristol Myers Squibb’s (BMS) admilparant, which is in a Phase III trial for IPF. In September 2025, United Therapeutics’ Tyvaso (inhaled treprostinil) showed benefit in the Phase III TETON-2 study (NCT05255991), with a significant 95.6mL increase in FVC from baseline. This data will tee the company up to apply for approval of the therapy in the US once it receives data from the TETON-1 trial (NCT04708782). EmphyCorp’s antioxidant, sodium pyruvate, is also in the registrational phase for IPF. Pharmaceutical Technology Excellence Awards - The Benefits of Entering Gain the recognition you deserve! The Pharmaceutical Technology Excellence Awards celebrate innovation, leadership, and impact. By entering, you showcase your achievements, elevate your industry profile, and position yourself among top leaders driving pharmaceutical advancements. Don’t miss your chance to stand out—submit your entry today! Nominate Now

Phase 3Drug ApprovalClinical Result

08 Oct 2025

·www.fiercepharma.com

Boehringer Ingelheim breathes new life into lung fibrosis field with FDA approval for Jascayd

Jascayd is Boehringer Ingelheim's second new drug approval this year, following up on recently approved oncology med Hernexeos (zongertinib). More than 10 years after bringing one of the first idiopathic pulmonary fibrosis (IPF) drugs to market, Boehringer Ingelheim is freshening up its leadership in the rare lung disease space with a newly approved treatment option.Jascayd's Oct. 7 FDA approval makes it the first new therapy for IPF in more than a decade, following in the footsteps of the company's own Ofev and Roche’s Esbriet, which won their respective FDA nods back in 2014. Together, those two medicines make up the current therapeutic market for IPF in the U.S. With a tolerability edge over the older treatments and proven benefits in lung function, Boehringer’s new option could “shape the future of IPF treatment,” Martin Beck, head of the company’s inflammation disease area, told Fierce Pharma in an interview.In trials, treatment with the oral twice-daily drug—also known as nerandomilast—resulted in a significantly smaller decline in patients' forced vial capacity (FVC) compared with those who received placebo. FVC is a common lung disease endpoint that measures the maximum amount of air a person can forcefully exhale after taking a deep breath.Jascayd’s benefits in slowing lung function decline and boosting lung volume could make the drug a crucial option for IPF patients, who face a progressive worsening of disease that causes more than half of patients to die within five years of diagnosis, Beck said.The disease is more deadly than many common cancers and could impact up to 3.6 million people across the globe, according to Boehringer. But, because it’s underdiagnosed and often misdiagnosed, only about 167,000 patients are currently receiving treatment, leaving a major gap in the market, Beck pointed out. While the drug didn’t meet the criteria to demonstrate a statistically significant survival benefit, it showed a “nominally significant reduction in risk of death” in patients with IPF and those with the related disease progressive pulmonary fibrosis (PPF), Boehringer announced last month, citing a pooled analysis.Still, Jascayd's profile represents a notable step forward in the IPF space, Beck said, describing the field as a “graveyard of clinical development” populated by more than 36 failed trials over the past decade.Now, the company is ready to make sure patients can access the new treatment option “as quickly as possible,” Beck said. Boehringer is poised to supply the drug “within days,” because “every day counts” for IPF patients, he added.“This is really a chance for those patients to have a chance to keep breathing, keep living,” the exec explained.Boehringer’s 10-plus years of experience in the IPF space with Ofev give the company a foundation for Jascayd's market entry. Still, Ofev is by no means old news as it remains a top seller for Boehringer, garnering $4 billion in sales last year.“To lead the next wave of innovation with nerandomilast is a true privilege for us at Boehringer and reflects our deep heritage in respiratory medicine as well as our unwavering commitment to additional treatment options for people living with IPF,” Shashank Deshpande, Boehringer’s head of human pharma, said in a statement. However, it remains to be seen whether Jascayd can live up to its blockbuster predecessor.Leerink analysts expect “solid uptake” on the drug given the limitations of the older treatments, the team wrote in a note to clients. But they argued the drug is a “modest advance due to relatively modest effect-size on lung function," which leaves room for future entrants.Jascayd’s approval is a "sign of a turning tide" in IPF drug development and a signal that the standard of care will look “significantly different” in the years to come, the analysts wrote in a note to clients. Several other companies are looking to get in on the IPF space, giving Boehringer plenty of competition on the horizon. United Therapeutics' nebulized inhalation solution Tyvaso, for one, delivered a phase 3 win last month in what United execs called “overwhelmingly positive” results.United and Boehringer are both also studying their respective drugs in PPF, another indication Boehringer is pursuing with the FDA.

Drug ApprovalPhase 3Clinical Result

100 Deals associated with Treprostinil sodium

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D06213 D08628	Treprostinil sodium	B01AC21	DB00374

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Hypertension, Pulmonary	United States	United Therapeutics Corp.	23 May 2022
Lung Diseases, Interstitial	United States	United Therapeutics Corp.	31 Mar 2021
Chronic thromboembolic pulmonary hypertension	European Union	SciPharm SARL	03 Apr 2020
Chronic thromboembolic pulmonary hypertension	Iceland	SciPharm SARL	03 Apr 2020
Chronic thromboembolic pulmonary hypertension	Liechtenstein	SciPharm SARL	03 Apr 2020
Chronic thromboembolic pulmonary hypertension	Norway	SciPharm SARL	03 Apr 2020
Pulmonary Arterial Hypertension	United States	United Therapeutics Corp.	21 May 2002

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Pulmonary hypertension due to interstitial lung disease	NDA/BLA	United States	Liquidia Corp.	19 Aug 2024
Progressive fibrotic interstitial lung disease	Phase 3	United States	United Therapeutics Corp.	30 Oct 2023
Progressive fibrotic interstitial lung disease	Phase 3	Argentina	United Therapeutics Corp.	30 Oct 2023
Progressive fibrotic interstitial lung disease	Phase 3	Australia	United Therapeutics Corp.	30 Oct 2023
Progressive fibrotic interstitial lung disease	Phase 3	Belgium	United Therapeutics Corp.	30 Oct 2023
Progressive fibrotic interstitial lung disease	Phase 3	Canada	United Therapeutics Corp.	30 Oct 2023
Progressive fibrotic interstitial lung disease	Phase 3	Chile	United Therapeutics Corp.	30 Oct 2023
Progressive fibrotic interstitial lung disease	Phase 3	France	United Therapeutics Corp.	30 Oct 2023
Progressive fibrotic interstitial lung disease	Phase 3	Germany	United Therapeutics Corp.	30 Oct 2023
Progressive fibrotic interstitial lung disease	Phase 3	Israel	United Therapeutics Corp.	30 Oct 2023

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT05255991 (TETON-2, Company_Website)	Phase 3	Idiopathic Pulmonary Fibrosis	597	Treprostinil	bwzxpsvhys(hkqkgfjjjq) = Tyvaso demonstrated superiority over placebo for the change in absolute FVC by 95.6 mL (Hodges-Lehmann estimate, p <0.0001) from baseline to week 52 in patients with IPF. xwsitaeswm (rglixgbera ) Met	Positive	02 Sep 2025
NCT05255991 (TETON-2, Company_Website)	Phase 3	Idiopathic Pulmonary Fibrosis	597	placebo		Positive	02 Sep 2025
NCT06129240 (ASCENT, ATS2025)	Not Applicable	Pulmonary hypertension due to interstitial lung disease	12	LIQ861	nqxgyyvzeg(kiunqkbyqj) = cpghehqbgo qsqrlymdzb (pojfemuupe, 164 - 448) View more	Positive	16 May 2025
NCT06129240 (ASCENT, ATS2025)	Not Applicable	Pulmonary hypertension due to interstitial lung disease	12	Placebo	nqxgyyvzeg(kiunqkbyqj) = efyinjmqke qsqrlymdzb (pojfemuupe, 148 - 420) View more	Positive	16 May 2025
ATS2025	Not Applicable	-	-	Treprostinil	xickvzihvy(vjbqqlznwu) = kiwxguodfs vgbxkthbht (vvnrnxyfbr )	-	16 May 2025
NCT06129240 (ASCENT, ATS2025)	Not Applicable	Lung Diseases, Interstitial	13	LIQ861	xbbgyawxqu(jgnpkzwxfw) = sdkrfsqmxp knifyakpdq (pfrrdahciu ) View more	Positive	16 May 2025
FREEDOM-EV (ATS2025)	Not Applicable	Pulmonary Arterial Hypertension NT-proBNP	153	Oral Treprostinil	byouxwzmgu(vvfovnzchs) = pdrguqwaaq ptxlenthuh (yyiaxjqlrk )	Positive	16 May 2025
FREEDOM-EV (ATS2025)	Not Applicable	Pulmonary Arterial Hypertension NT-proBNP	153	Placebo	byouxwzmgu(vvfovnzchs) = lhqpogbgit ptxlenthuh (yyiaxjqlrk )	Positive	16 May 2025
NCT03950739 (BREEZE Optional Extension \| BREEZE, CTgov)	Phase 1	Pulmonary Arterial Hypertension	51	Treprostinil Inhalation Powder	bswnzuyoer(txknazftyn) = ctzimflhiu dcssebdfoy (jmptdfyast, 32.9) View more	-	01 Nov 2024
ESC2024	Not Applicable	Pulmonary Arterial Hypertension	-	Treprostinil	qzwqjnlrnt(zugvvcnnqv) = hbfawnxpza luzwfdchux (rjqlskrwii, 10.42 - 19.90)	-	02 Sep 2024
ESC2024	Not Applicable	Pulmonary Arterial Hypertension	-	Placebo	-	-	02 Sep 2024
NCT03399604 (INSPIRE, CTgov)	Phase 3	Idiopathic pulmonary arterial hypertension	121	LIQ861 Inhaled Treprostinil	ekcqbrfpcc = batxpaxhxe ebauovmymm (nzzrrmcjzu, fcbaekxfij - hbrjjfprrd)	-	30 Jul 2024
NCT04691154 (ATS2024) Manual	Phase 3	Pulmonary Arterial Hypertension \| Pulmonary hypertension due to interstitial lung disease	15	L606	rudeoyexjo(hyervujmnw) = ggavsvufkz nsqfspqhkz (zwgrufvbul ) View more	Positive	22 May 2024
NCT03497689 (EXPEDITE, ATS2024)	Phase 4	Pulmonary Arterial Hypertension	29	Parenteral treprostinil	wanehagzrv(yxkwpcvtke) = nkufzmtmpq taftcxuihr (uzrlhawegl, 23 - 46)	Positive	19 May 2024